Ativan, Loraxepan contains PEG

[Guest guest]

Notice the symptoms and how the same symptoms follow the chemical in different medications, anyone see a pattern here..............give this to your doctor. Anything that has PEG has these side effects but because the protocol is WRONG, they aren't connecting the two........................PEG is absorbed and DOES cause these side effects, If you do your research you will see.................

The parenteral formulation of lorazepam contains polyethylene glycol and propylene glycol. Each agent has been associated with specific toxicities when administered in prolonged infusions at high dosages. Also contains benzyl alcohol - avoid rapid injection in neonates or prolonged infusions. Intra-arterial injection or extravasation should be avoided. Concurrent administration with scopolamine results in an increased risk of hallucinations, sedation, and irrational behavior.

Causes CNS depression (dose-related) resulting in sedation, dizziness, confusion, or ataxia which may impair physical and mental capabilities. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive agents. Effects with other sedative drugs or ethanol may be potentiated. Benzodiazepines have been associated with falls and traumatic injury and should be used with extreme caution in patients who are at risk of these events (especially the elderly).

Lorazepam may cause anterograde amnesia. Paradoxical reactions, including hyperactive or aggressive behavior have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients. Does not have analgesic, antidepressant, or antipsychotic properties.

Use caution in patients with depression, particularly if suicidal risk may be present. Use with caution in patients with a history of drug dependence. Benzodiazepines have been associated with dependence and acute withdrawal symptoms on discontinuation or reduction in dose. Acute withdrawal, including seizures, may be precipitated after administration of flumazenil to patients receiving long-term benzodiazepine therapy.

As a hypnotic agent, should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation.

Adverse Reactions

>10%:

Central nervous system: Sedation

Respiratory: Respiratory depression

1% to 10%:

Cardiovascular: Hypotension

Central nervous system: Confusion, dizziness, akathisia, unsteadiness, headache, depression, disorientation, amnesia

Dermatologic: Dermatitis, rash

Gastrointestinal: Weight gain/loss, nausea, changes in appetite

Neuromuscular & skeletal: Weakness

Respiratory: Nasal congestion, hyperventilation, apnea

<1%: Blood dyscrasias, increased salivation, menstrual irregularities, physical and psychological dependence with prolonged use, reflex slowing, polyethylene glycol or propylene glycol poisoning (prolonged I.V. infusion)

Overdosage/ToxicologySymptoms of overdose include confusion, coma, hypoactive reflexes, dyspnea, labored breathing. Note: Prolonged infusions have been associated with toxicity from propylene glycol and/or polyethylene glycol. Treatment for benzodiazepine overdose is supportive. Flumazenil has been shown to selectively block the binding of benzodiazepines to CNS receptors, resulting in a reversal of benzodiazepine-induced CNS depression but not respiratory depressionhttp://www.umm.edu/altmed/drugs/lorazepam-077600.htm